Dirt Doctors: ProGro BIO Healing the American Acre

ProGro BIO launches two microbial powerhouses for 2026, targeting soil recovery and nitrogen fixation as synthetic costs continue to climb

6 May 2026

ProGro BIO has launched two microbial soil products for the 2026 US growing season, as elevated synthetic input costs and tightening nutrient runoff rules push growers to consider biological alternatives. The company, which reported sales growth of more than 300 per cent in 2025, is expanding its platform at a moment of growing regulatory and commercial pressure on conventional farm chemistry.

Their first product, Rhizol JumpStart, is aimed at peanut growers. It delivers a dry form of Bradyrhizobium, a bacterium that converts atmospheric nitrogen into a form plants can absorb directly, reducing dependence on synthetic nitrogen fertilisers. Each package treats up to 40 acres.

Liquid inoculants have historically suffered from poor shelf stability, limiting their reliability at commercial scale. ProGro says the dry formulation extends viable shelf life significantly beyond liquid equivalents while maintaining efficacy in the field.

The second product, Phoenix, is designed to restore soils damaged by fumigation, stover burning, and intensive tillage, practices that strip the microbial communities underpinning soil fertility. Phoenix applies 29 microbial species alongside humic and fulvic acids at 15 grams per acre.

ProGro cited soil sample data from more than 1,000 analyses conducted through the North Carolina Department of Agriculture, which it said showed humic matter gains of 5.7 per cent. Multi-year US trials, the company added, have shown yield improvements ranging from 5 per cent to above 20 per cent.

Moreover, the company is closing a Series A funding round. Proceeds are earmarked for sales and marketing rather than further research and development, signalling a shift toward commercial scaling. Whether that pace of expansion can be sustained as more biological input firms compete for the same grower base remains an open question.